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Abstract:  Early diagnosis of cancer is of pivotal importance to reduce disease-related 
mortality. There is great need for non-invasive screening methods, yet current screening 
protocols have limited sensitivity and specificity. The use of serum biomarkers to 
discriminate cancer patients from healthy persons might be a tool to improve screening 
programs. Mass spectrometry based proteomics is widely applied as a technology for 
mapping and identifying peptides and proteins in body fluids. One commonly used 
approach in proteomics is peptide and protein profiling. Here, we present an overview of 
profiling methods that have the potential for implementation in a clinical setting and in 
national screening programs. 
Keywords: mass spectrometry; biomarker; MALDI-TOF; SELDI-TOF; colorectal cancer; 
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1. Introduction  
Population wide screening programs are used to detect early stage cancer to enable early 
intervention and reduce morbidity and mortality. Ideally screening tests have to be highly specific, 
sensitive, cost-effective and non-invasive. The development of new screening methods has become 
important due to an increasing incidence, as is the case for colorectal cancer (CRC). In addition, novel 
screening strategies aim at improved sensitivity and specificity in case of breast cancer. Advanced 
cancer has a poor survival, whereas when diagnosed at an early stage, survival is relatively good [1]. 
Early detection will identify cancer when it is still localized and curable, preventing not only mortality, 
but also reducing morbidity and costs [1–5]. The use of serum biomarkers as an indicator of disease in 
cancer screening programs could provide a promising alternative to existing methods. 
A biomarker, or biological marker, is a biomolecule that can be used as an indicator of a disease, 
based on abnormal presence, absence or changes in genes, RNA, proteins or metabolites. In this 
manuscript we will discuss protein biomarkers. The ideal biomarker is both highly specific and 
sensitive. For screening programs, the required measurements have to be reliable, robust, fast, and 
economical. The material containing the marker(s) should be easily obtainable and have a 
patient-friendly application. In this respect, body fluids such as serum are suitable sources of 
biomarkers. Possible applications are (early) detection, prediction of survival and prediction and 
monitoring of response to therapy. Here we focus on the use of protein biomarkers for early   
cancer detection. 
The translation of the DNA code results in protein expression. In contrast to the genome, the 
proteome reflects a more dynamic state of the cell [6]. During transformation of a normal cell into a 
neoplastic cell, distinct changes occur at the protein level, including altered expression, different 
protein posttranslational modifications, changes in specific activity and inappropriate localization, all 
of which may affect cellular function [4,7]. By comparing the protein patterns, i.e., profiles, in serum 
from patients with cancer with those obtained from healthy individuals, proteins that are the most 
discriminating can be classified. The resulting protein fingerprint has the potential to identify a person 
with cancer. Mass spectrometry (MS) has proven to be a powerful tool in obtaining such protein 
fingerprints due to its high sensitivity and specificity. In fact, proteomic research has benefitted 
enormously from developments in MS technology and has evolved into a new field that is referred to 
as MS-based proteomics [8]. Whereas proteomics aims for the full identification and quantification of 
all expressed proteins, profiling strategies usually are applied on sub-sets of the proteome. Importantly, 
all steps in MS based profiling methods can be fully automated allowing high sample throughput and 
standardization [9]. In finding biomarkers for early cancer detection, the content of this review is 
limited to results obtained from protein profiling efforts. 
2. Screening for Breast Cancer and Colorectal Cancer 
2.1. Breast Cancer 
Breast cancer is the most commonly diagnosed malignancy in women with over one million new 
cases in the world each year [10]. With an increasing lifetime risk, currently estimated at one in eight, 
it is a leading cause of cancer-related morbidity and mortality. Despite increasing incidence rates, Int. J. Mol. Sci. 2010, 11                 
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annual mortality rates from breast cancer have decreased over the last decade [11]. Reasons for this 
decline include precise diagnosis, increased number of women receiving tailor made treatment, such as 
extensive use of tamoxifen, and the use of chemotherapy and early detection through widespread 
mammography screening [10,12].  
Mammography is currently the most important tool in screening and early detection of breast 
cancer [10]. In many countries, mammography is used as a population based screening method in 
women over 50 years of age. However, up to 20% of new breast cancer incidents are not detected by 
this method [13–15]. Furthermore, only one out of three lesions positively detected using 
mammography turns out to be malignant. Mammography is also used as a screening tool in young 
women with a high familiar risk or with a genetic predisposition. In this group the detection rate is 
only 40%, mainly because of the dense breast tissue [16,17]. Adding MRI to mammography screening 
for these at risk patients has good potential to detect mammographically occult cancers but this 
expensive imaging technique does not reliably distinguish benign from malignant findings and has a 
high false positive rate [18–20]. Consequently, MRI and also mammography screening can lead to 
overdiagnosis and overtreatment [18,21], indicating a need for novel molecular markers that might 
improve specificity and sensitivity for early detection of breast cancers, suitable for population 
screening or more intensified screening programs for young women with an increased risk.  
2.2. Colorectal Cancer 
Colorectal cancer (CRC) is among the most common malignancies and remains a leading cause of 
cancer-related morbidity and mortality. There are approximately one million new cases of CRC per 
year worldwide [22]. Although the incidence of CRC is fortunately decreasing in the United 
States [9,23], in most other countries the incidence rates are increasing, particularly due to the increase 
in total population and aging of the current population. In Asia, Eastern Europe, Israel, and Puerto 
Rico the increase is most dominant. Colorectal cancer arises from a multistep sequence of genetic 
alterations that results in the transformation of normal mucosa to a precursor adenoma and ultimately 
to carcinoma. Early detection appears to be the most influential factor to reduce disease related 
mortality and treatment related morbidity [23,24]. Unfortunately, at this moment only about 37% of 
CRC remain localized at the time of diagnosis [25]. Survival in CRC is directly related to the stage of 
the disease at the time of diagnosis. When cancer is found early at localized stage (stage I), five-year 
survival is approximately 95% [9,26]; whereas the overall five-year survival rate of CRC with distance 
metastasis to distance is less than five percent. Early detection by population wide screening programs 
thus becomes more important. 
Access to screening programs varies throughout the world, from population programmatic 
screening in developed countries to regional level screening programs or the opportunity of having a 
screening test when entering a health care system. Screening programs in most countries include 
average risk individuals aged between 50 and 75 years [22] and vary widely in screening incidence as 
well as in the method of choice. 
Currently available tests used for screening include guaiac-based fecal occult blood test (gFOBT), 
immunochemical fecal occult blood test (iFOBT), colonoscopy and flexible sigmoidoscopy (FS). Int. J. Mol. Sci. 2010, 11                 
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Other less commonly used tests are stool DNA testing (sDNA), computed tomography colonography 
(CTC) and double-contrast barium enema (DCBE).  
Due to its low costs and easy access, the most frequently used screening method is gFOBT. It 
detects the peroxidase reaction of hemoglobin. Disadvantages are the false–positive rates which make 
dietetic provisions necessary and low sensitivity rates from 20–40% [27]. 
With iFOBT, no dietetic restrictions are necessary because it only reacts to human hemoglobin. A 
wide range of qualitative and quantitative tests are presently available, with varying levels of 
sensitivity and specificity. With only one test, sensitivity rates are approximately 65%; when repeated 
every two years, sensitivity increases to 80–90% [28,29]. 
FS is an endoscopic examination with maximum reach to the splenic flexure. Its sensitivity is about 
60–70% for adenomas and CRC [30,31]. Unlike FS, colonoscopy also detects lesions in the proximal 
colon. Its biggest advantage is the possibility of removing pathological lesions within a single 
examination. The sensitivity in detecting both adenomas and carcinomas seems to be high but data 
from prospective, randomized trials are limited. Also it is an invasive method with a higher risk of 
serious adverse events than for FS, respectively 3–5% compared to 0% to 0.03% [30,32,33]. To 
implement colonoscopy into national screening programs, a huge increase in care capacities would  
be necessary.  
sDNA examines the stool for the presence of abnormal DNA. The test sensitivity for CRC ranges 
from 52% to 91% [27,34–36]. Another disadvantage is its high price. 
CTC shows lesions in the colorectum by reconstructing two- and three-dimensional images. To 
date, no studies have been published assessing reduction in CRC incidence or mortality. DCBE shows 
the entire colorectum, although with significantly lower sensitivity and specificity than colonoscopy or 
CTC. The percentage of undetected carcinomas is up to 22% [33]. 
No available CRC screening test is yet perfect, either for cancer detection or adenoma detection. 
Each test has associated limitations and risks. There is a great need for alternative, non-invasive 
methods with high sensitivity and specificity rates, easily available and cost effective. Use of MS 
based proteomic serum biomarkers could form a specific, more sensitive and less invasive alternative.  
3. Workflow in Proteomic Profiling 
3.1. Blood Sample Preparation 
Human blood is a suitable source of proteins and can be obtained in a relatively easy fashion. Both 
plasma and serum samples, obtained from whole blood, have been used in biomarker discovery 
studies. Serum resembles plasma in composition but lacks the coagulation factors. Although serum is 
preferred for many tests because the anticoagulants in plasma can sometimes interfere with the 
method, plasma seems to be more stable than serum and more suitable for analysis of the 
low-molecular-weight proteome. It has been reported by various authors that protein profiles obtained 
from plasma and serum differ and unfortunately at this time it would appear that insufficient 
information is available to decide whether serum or plasma should be preferentialized in MS-based 
proteomics studies aiming for biomarker discovery. While most studies have been carried out using 
serum, further research on this topic is required. A temporary solution would be to use both, however 
this would complicate data analysis and require longer processing times.  Int. J. Mol. Sci. 2010, 11                 
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3.2. Standardization 
As is the case for all diagnostic tools in a clinical setting, MS based proteomic profiles should be 
precise and accurate, and the methodology needs to be robust and reproducible. Some critics have 
argued that discriminating peaks are influenced by various factors. Possible confounding factors can 
be categorized into three sources of variation and bias: biological variation, pre-analytical variation 
and analytical reproducibility. Examples of biological variation are race, age, diet, smoking, but also 
stress, drugs and general physical conditions [37–39]. To date, no studies have been reported taking 
into account these latter aspects. Some groups have reported data on the effects of different sample 
preparation procedures. In all studies the importance of sample handling was indicated; i.e., the time 
between blood sampling and serum centrifugation. A delay of two to four hours seems to be 
acceptable. De Noo et al. analyzed pre-analytical variables and reproducibility on a matrix-assisted 
laser desorption ionization time-of-flight (MALDI-TOF) approach.  
It is now generally recognized that standardized sample collection is required for clinical 
studies [40,41]. In addition, it is recommended that the number of freeze/thaw cycles is kept as low as 
possible. Finally, it was found that circadian rhythm was not an influencing factor, in other words 
samples can be collected at any time of the day. Both the acceptable delay time before serum 
centrifugation and the ability to collect samples throughout the day increases future clinical 
applicability [38].  
The Human Proteome Organisation (HUPO) is an international scientific organization representing 
and promoting proteomics through international cooperation and collaboration by fostering the 
development of new technologies, techniques and training. (www.hupo.org). For this review, 
interesting HUPO initiatives are the HUPO Plasma Proteome Project (HPPP) and Human Proteome 
Project (HPP). A goal of the first initiative is to organize more standardized procedures regarding the 
collection and measuring of the samples and data processing. An overview of the HPPP results from 
the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core 
dataset of 3020 proteins and a public database [42]. The mission of the HPP is to characterize all 
21,000 genes of the known genome, thus generating a map of the protein based molecular architecture 
of the human body and providing a resource to help elucidate biological and molecular function and 
advance diagnosis and treatment of diseases[43].  
3.3. Clean-up Procedure 
Human body fluids such as serum are complex mixtures of salts, lipids, peptides and proteins. To 
carry out a repeatable and robust mass spectrometric analysis of proteins in body fluids, a clean-up or 
extraction procedure is required [44]. In general, protein separation techniques are based on different 
physical properties of a protein, such as size, iso-electric point, solubility and affinity. Furthermore, the 
use of a specific agent to capture proteins enriches the sample and thus improves the lower limits of 
detection. Obviously, enrichment procedures are of great value to capture so-called low-abundance 
proteins. Unfortunately, low-abundance proteins are often not circulating freely but are specifically 
bound to high-abundance proteins, such as albumin. As a result proteins present at low concentration 
can be lost in depletion methods [9].  Int. J. Mol. Sci. 2010, 11                 
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3.4. Functionalized Magnetic Beads 
In the last decade, multiple studies have been carried out using magnetic beads as a method for off-
line serum peptide/protein capture [38,45–47]. Magnetic beads are uniform beads specifically designed 
for quick manual or automated fractionation of proteins or peptides from complex biological samples. 
This solid-phase extraction (SPE) procedure is quick and simple, sample preparation occurs without 
the need for laborious pipetting and centrifugation. As mentioned earlier, protein separation techniques 
are based on different physical properties of a protein. Materials known from these different 
chromatographic platforms are coupled to the surface of spherical magnetic beads. Magnetic beads 
most applied in studies are WCX (weak cation exchange), RPC18 beads (reversed phase) and C8. 
WCX beads separate proteins based on charge, whereas RPC18 beads separate proteins and peptides 
via strong hydrophobic interaction[48]. 
3.5. Automation 
The manual fractionation and processing steps are tedious and time consuming to perform. 
Automation ensures reproducibility and facilitates high-throughput performance necessary for large 
scale studies. In the last few years our study group developed a reliable automated technique that is 
specially designed for high-throughput sample handling, i.e., processing hundreds of serum samples 
per day. The activation, wash and desorption steps of WCX and RPC18 beads are based on the 
manufacturers protocol, with adjustments to allow for optimal implementation on a 96-channel 
Hamilton STARplus
® pipetting robot. With this liquid handling robot, the whole serum peptide/protein 
capture procedure is automated. Spotting onto a MALDI target plate is carried out in quadruplicate 
using the same robot. 
3.6. MALDI-TOF Mass Spectrometry 
Mass spectrometry (MS) is the method of choice for the analysis of proteins in serum [8]. A mass 
spectrometer separates peptides or proteins according to their mass-to-charge ratio. A mass 
spectrometer consists of an ion source, a mass analyzer and a detector. There are several types of mass 
spectrometers, the one mostly used in profiling strategies is MALDI-TOF. To carry out a 
MALDI-TOF mass analysis, a small amount of specimen containing peptides and proteins is dried on a 
target plate after mixing with a light-absorbing matrix. MALDI-TOF MS is a rapid biomarker 
discovery tool that allows high-throughput screening through automated sample processing and 
profiling.  
3.7. SELDI-TOF 
As an alternative, surface enhanced laser desorption ionization-time-of-flight (SELDI-TOF) can be 
used [49]. In SELDI-TOF a surface modified with a chemical functionality on a chip is used. A sample 
clean-up is then carried out on this chip similar to workup with functionalized magnetic beads. Some 
proteins in the sample bind to the chip surface, while the others are removed by washing. After 
washing the spotted sample, the matrix is applied to the surface and allowed to crystallize with the 
sample peptides. Common surfaces include CM10 (weak-positive ion exchange), H50 (hydrophobic Int. J. Mol. Sci. 2010, 11                 
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surface, similar to C6C12 reverse phase chromatography), IMAC30 (metal-binding surface), and Q10 
(strong anion exchanger). Surfaces can also be functionalized with antibodies, other proteins or DNA. 
Samples spotted on a SELDI surface are mass analyzed using TOF-MS as used in MALDI-TOF. 
Combined with magnetic bead fractionation, MALDI-TOF has higher throughput than SELDI-TOF 
and is more sensitive, as spherical particles have larger surface areas and higher binding capacity than 
chips. Thus, in SELDI-TOF more serum is necessary for analysis. 
3.8. Data Analysis 
Next to standardized sample collection and preparation protocols, the data analysis is of major 
importance. In 2008, our group organized a competition on clinical mass spectrometry based 
proteomic diagnosis. Eleven international statistical groups participated and constructed a diagnostic 
classification rule for allocation of future patients on a blinded calibration set. This classification rule 
was then tested on a blinded validation set. A variety of statistical methods was used to create a 
classification rule. Mertens and co-workers described a method in which classification error rates were 
estimated and validated based on a classical Fisher linear discriminant analysis through complete 
double cross validation [50]. Each sample was assigned to the group for which the probability was 
highest. Other groups, for example, used the random forest classification method, or a three-step 
approach with ranking of the mass/charge values using random forests, then grouping into new 
variables and finding a discriminating rule by penalized logistic regression. For further details and 
additional statistical methods see http://www.bepress.com/sagmb/vol7/iss2. This competition showed 
that a discriminating profile could be created independently of the chosen statistics with consistent 
results of 80% accuracy [51].  
4. Potential Mass Spectrometry Derived Biomarkers  
4.1. Early Detection of Breast Cancer 
Several studies have used mass spectrometry (MS) on serum samples in an attempt to find 
biomarkers for early diagnosis of breast cancer using the SELDI-TOF [52–58] or MALDI-TOF 
approach [45]. All studies were case controlled, except for the study by Mathelin et al. The various 
studies included sample sizes from 40 to 109 cancer patients with control groups of equal size. Results 
were encouraging with high sensitivity and specificity rates, varying from 80 to 100%. Several 
discriminatory peaks were described, such as a peak at 8.9 kDA [52,53,56,59], 4.3 kDa [56–58] and 
one at 8.1 kDa [53,56]. 
However, the reproducibility of these results has been questioned. Li et al. identified three peaks 
associated with breast cancer, termed BC1 (4.3 kDa), BC2 (8.1 kDa) and BC3 (8.9 kDA) [56]. The 
combination of these three biomarkers allowed differentiation of cancer patients and non-cancer 
controls with a sensitivity of 93% and specificity of 91%. Mathelin et al. tried to validate these three 
biomarkers in a set of 49 breast cancer patients and 13 patients with benign breast tumors and 27 
controls [58]. Although, both of these studies used SELDI-TOF and nickel-loaded proteinchip arrays, 
Mathelin et al. could not identify the BC2 peak in their patient series. A combination of BC1 and BC3 
could only identify 45% of all breast cancer patients successfully. This is a somewhat disappointing Int. J. Mol. Sci. 2010, 11                 
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result that might indicate that results obtained in one laboratory are difficult to reproduce in another 
laboratory or setting. Although limited information concerning handling protocols was provided in the 
reports of these two studies, differences in methods might have been responsible for this lack of 
reproducibility [60]. Remarkably, another study found that the peak at 8.9 kDa was decreased, whereas 
in other studies this peak was increased [61]. Even a follow-up study by the same group could not 
reproduce the BC1 peak [62].  
All described differences can be due to modification of peptides or proteins from the moment of 
sample collection to freezing, which has been described [63]. Some of these studies used different 
methods with regard to time between collection and freezing, time of centrifugation, and storage 
freezing temperature, which may well lead to variability in outcome. Results by Fan et al. were more 
optimistic. This study tested a classification model after initial identification in a different patient 
group. On a blinded patient population, this model had high sensitivity and specificity (96.45% and 
94.87% respectively) [53], indicating a good reproducibility if MS is performed under the exact same 
conditions (Table 1). 
Table 1. Early detection of breast cancer. 
Study   MS Method 
Study Size 
N = 
Sensitivity Specificity  External  Validation? 
Hu et al. The Breast 
2005 [52] 
SELDI-TOF 
49 BC 
51 BBD 
33 HC 
83.33% 88.89% 
Yes 
N = 18 BC, 9HC 
Fan et al. Journal of 
Cancer Research and 
Clinical Oncology 
2010 [53] 
SELDI-TOF 
80 BC 
40 HC 
96.45% 94.87% 
Yes 
N = 44 BC, 98 BBD, 20 
HC  
Belluco et al. Annals 
of Surgical Oncology 
2007 [54] 
SELDI-TOF 
109 BC 
109 HC 
95.6% 86.5% 
Yes 
N = 46 BC, 46 HC 
Callesen et al. 
Journal of Proteome 
Research 2008 [55] 
SELDI-TOF 
48 BC 
28 HC 
85% 85%  No 
Li et al. Clinical 
Chemistry 2002 [56] 
SELDI-TOF 
103 BC 
25 BBD 
41 HC 
93% 91%  No 
Vlahou et al.  
Clinical Breast 
Cancer 2003 [57] 
SELDI-TOF 
45 BC  
42 BBD 
47 HC 
80% 79%  No 
De Noo et al. 
Onkologie 2006 [45] 
MALDI-TOF 
78 BC  
29 HC 
100% 97%  No 
BC = Breast cancer, BBD = Benign breast disease, HC = Healthy controls. 
 
Like in colorectal cancer, the size of the investigated groups was relatively small. Some studies 
found MS differentiated benign from malignant abnormalities [52], but most studies used healthy 
people as controls which obviously is not representative of the general patient population. Int. J. Mol. Sci. 2010, 11                 
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4.2. Early Detection of CRC 
Mass spectrometry has been applied for the development of tests for early diagnosis of CRC in 
several studies [64–70]. All of these were case-control studies and, so far, no prospective or 
randomized studies have been reported. Published studies reported promising results and underline the 
potential of mass spectrometry for early diagnostics. Patients diagnosed at several stages of colorectal 
cancer were included these studies (Dukes stage I to IV). Although for all mentioned studies serum 
samples were used, the applied methods differed. Only de Noo et al. used MALDI-TOF MS in 
combination with C8 magnetic beads, while all others used the SELDI-TOF system with varying 
detection chips. For instance, Engwegen et al. found the best results by using CM10 chips, while 
Liu et al. compared obtained serum profiles with several chips and found the best results using the 
IMAC30 chip with the SELDI-TOF system. More research has to be done to optimize pre-analytical 
and detection variables. However, Ward et al. and Liu et al. found reproducible results when identical 
methods and materials were used. Various studies show many variations in methods for storage and 
handling of the serum samples, the time period between sample collection and freezing, and samples 
being stored at different temperatures.  
The aforementioned studies used discriminant analysis to discriminate between cancer patients and 
healthy controls. Interestingly, several peaks were repeatedly found in multiple studies signifying their 
potential as a biomarker. For instance, a peak at m/z ratio 8940 Da (identified as complement protein 
C3a-desArg) was found by Ward et al., Habermann et al., Zhao et al. and Yu et al. Another peak at 
5911 Da was used as a discriminating peak both by Yu et al. and by Chen et al. Most studies tried 
several combinations of significant peaks and used those to identify cancer patients. All studies were 
capable of achieving sensitivity and specificity values of around 90% or higher. However, we have to 
be cautious since these results might be overoptimistic. Since some of the algorithms were tested on 
the same group of patients which was used to create the algorithm, results might be biased. Also, 
relatively small groups were used in these studies (40 to 60 colorectal cases with control groups 
consisting of a similar size of healthy controls). Validation of these results on a larger and independent 
patient group is therefore necessary. Some of the published studies used a (small) independent group 
for validation of the sensitivity and specificity [65,68,71]. Engwegen et al. validated their 
classification tree on independent patient samples, from which a test sensitivity and specificity of 
66.7% and 89.5% were found. Liu et al. found a sensitivity of 95% and specificity of 94.87% when 
testing their biomarkers on a set of 60 cancer patients and 39 healthy subjects (Table 2). 
However, the reason these techniques are being developed is for screening in patient populations 
where the a priori chance of having colon cancer is much smaller than in the patient series in these 
studies. With a lower a priori chance, the positive predictive value will most likely be lower. First 
trials on large representative patient populations or patients with an increased risk of colorectal cancer 
are therefore essential.  
 
Table 2. Early detection of CRC. 
Study MS  Method 
Study Size 
(N) 
Sensitivity Specificity  External  validation? Int. J. Mol. Sci. 2010, 11                 
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Yu et al. World J 
Gastroenterology 2004 [64] 
SELDI-TOF 
55 CRC 
35 CRA 
92 HC 
89% 83–92%  No 
Liu et al. Cancer 
Investigation 2006 [65] 
SELDI-TOF 
74 CRC 
48 HC 
95% 94.87% 
Yes 
N = 60 CRC, 39 HC 
De Noo et al.  
European Journal of Cancer 
2006 [45] 
MALDI-TOF 
66 CRC 
50 HC 
95.2% 90.0%  No 
Ward et al.  
British Journal of Cancer 
2006 [67] 
SELDI-TOF 
62 CRC 
31 HC 
95% 91%  No 
Chen et al. Clinical Cancer 
Research 2004 [69] 
SELDI-TOF 
55 CRC 
92 HC 
91% 93%    No 
Zhao et al. Chinese Journal 
of Clinical Medicine 2004 
[70] 
SELDI-TOF 
73 CRC 
16 CRA 
31 HC 
96% 98% 
Yes 
N = 73 CRC, 16 CRA, 
31 HC 
Engwegen et al.  
World Journal of 
Gastroenterology 2006 [68] 
SELDI-TOF 
77 CRC 
80 HC 
66.7–89.5% 73.3–88.9%  Yes 
CRC = Colorectal adenoma, CRA = Colorectal adenoma, HC = Healthy controls. 
5. Identification of Biomarkers 
The first studies investigating the possibility of early diagnosis of breast and colorectal cancer with 
mass spectrometry did not include identification of discriminating peaks. Ideally, these would all be 
proteins produced by tumor cells only and secreted into the blood in sufficient quantities to be 
detected. The identification of discriminatory proteins has become an important element in recent 
studies and will be discussed below.  
Identifying proteins is by no means simple and requires additional analytical tools. In the early 
days, MALDI-TOF mass fingerprinting was used for MS-based protein identification. To this end, a 
protein is enzymatically converted into peptides, typically with trypsin. Since the tryptic digestion is 
highly site-specific, the identification of at least two peptides allows identification of the original 
protein. This method, however, only works for purified proteins. Nowadays, the method of choice for 
protein identification is tandem mass spectrometry (MS/MS or MS
2). The tryptic peptides are first 
separated using high-performance liquid chromatography (HPLC) before performing MS/MS 
identification. The HPLC is interfaced with a tandem mass spectrometer through an electrospray 
ionization (ESI) source. So-called LC-MS/MS methods are highly suited and optimized for peptide 
sequencing. Sequencing experiments (i.e.,  MS/MS) are carried out on ions that are selected in a 
prescan (i.e.,  MS). Peptides are collided with inert gas which causes these peptides to fragment, 
resulting in product ions that can be interpreted with respect to the primary amino acid sequence. The 
resulting spectra are used to identify the peptides in question. This can be done in various ways; by de 
novo sequencing or by spectral matching using databases. With de novo sequencing, the amino acid 
sequence of a peptide is reflected in the fragment ion mass spectrum. The mass difference between two Int. J. Mol. Sci. 2010, 11                 
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neighboring peaks is equal to the mass of one amino acid. However, when not all peptide bonds are 
broken, or when all expected fragment ions do not appear in the mass spectrum, interpretation may be 
ambiguous. Therefore, spectral matching is more frequently used. This method identifies peptides by 
comparing an MS/MS-spectrum with theoretically expected peptide spectra that are stored in a 
database. After comparison, the best matching peptide(s) are given together with a score indicating the 
closeness of the match. This database (SpectraST for example) consists of a collection of theoretical 
spectra that are derived from all possible proteins that can originate from the genome. These databases 
take certain splice-variants into account; however the existence of alternative splice variants or 
mutations, related for instance to cancer, hampers the identification of peptides. A related problem 
with this approach is the redundancy of proteins that do not actually occur, and thus the chance of 
accidental matches is increased. Another possibility, is matching the spectrum of product ions to 
spectra that were obtained from standard (synthetic) or previously identified peptides. This approach 
has the advantage that the database does not include any proteins that are not naturally present and 
thus decreases the number of false positives. Obviously, the disadvantage is that it cannot be used to 
identify proteins that are not included in the database. Note the difference between peptide and protein 
identifications, that is, the peptides are identified directly from the MS/MS-spectra, with a certain 
confidence, whereas a protein identification is derived from a combination of multiple peptide ID’s. 
Several parameters exist to express the reliability of the peptide and resulting protein matches. The 
mathematics and statistics that are used for this purpose fall beyond the scope of this review but are 
reviewed elsewhere [72]. The reliability of protein identification can be increased by using known 
properties of the yet unidentified protein. For instance, if the protein is also analyzed on SDS-PAGE, 
its mass can be identified and proteins that have a different mass can be left out of the database 
analysis. Some studies have used western blotting to identify proteins on SDS-PAGE after 
identification which is an effective method to confirm protein identity, if reliable antibodies are 
available. 
5.1. Biomarker Identification in Breast Cancer 
Only limited studies have identified biomarkers in MS studies for breast cancer. Li et al. tried to 
identify their previously identified BC1-3, but could only identify BC2 and BC3 as fragments of C3a, 
desArg [62]. This protein was also identified in colorectal and MS studies in other forms of cancer. 
The BC1 is suspected to be an interalpha-trypsin inhibitor heavy chain H4. Fan et al. found 
apolipoprotein C-I to be down-regulated in breast cancer patients. The two other discriminatory peaks 
were identified as C-terminal-truncated form of C3a and its complement component C3a [53]. As in 
colorectal studies, the previously identified proteins might seem to be lacking in specificity as these 
are not tumor-produced proteins. However, Villanueva et al. described not only cancer-specific, but 
cancer type-specific biomarkers [63]. The strength of this study was that it was the first, not only to 
take the identity of the potential biomarkers into account, but also to realize the importance of the 
biomarkers’ mass. This study found 11 unique biomarkers for breast cancer compared to prostate 
cancer and bladder cancer patients. These were all protein fragments cleaved from proteins normally 
present in the serum (fibrinogen α, C4a, C3f, ITIH4, ApoA-IV and transthyretin). Further research into 
these 11 biomarkers might find a set of unique biomarkers for breast cancer. It therefore seems that the Int. J. Mol. Sci. 2010, 11                 
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biomarkers that are discovered with MS are not tumor-specific proteins, but tumor-specific protein 
fragments. This may well be due to tumor-specific secretion of proteases which cleave high-abundant 
serum proteins (Table 3). 
Table 3. Biomarker identification in breast cancer. 
Author  Identified biomarkers (m/z ratio) 
Li et al. Clinical Chemistry 2005 [62]  C3 fragment (8.1 × 10
3/8.9 × 10
3) 
Fan et al. Journal of Cancer Research 
and Clinical Oncology 2010 [53] 
Apolipoprotein C-I (6.6 × 10
3) 
C3 fragment (8.1 × 10
3/8.9 × 10
3) 
Villanueva et al. Journal of Clinical 
Investigation 2006 [63] 
FPA, fibrinogen alpha, C3f, C4a, ITIH4, ApoA-IV, 
Bradykinin, Factor XIII, Transthyretin 
5.2. Biomarker Identification in Colorectal Cancer 
One of the most frequently found potential biomarkers, C3a-desArg, is not a tumor secreted protein, 
but a component of the complement system. Elevation of this protein is therefore more likely to be a 
reflection of the body’s inflammatory response activated by cancer. Interestingly, using serum ELISA 
testing of C3a-desArg levels, Habermann et al. were able to identify cancer patients with a sensitivity 
of 96.8% and specificity 96.2%. However the control group in this study consisted of healthy medical 
personnel. This group was not age matched and might therefore have a relatively lower chance of 
additional diseases than a screening population aged 50–75 years, which might lead to nonspecific 
elevation of C3a-desArg levels. For instance, Li et al. also reported an elevation of C3a-desArg in 
patients with breast cancer [62]. This implies that the elevation of these proteins is in fact non-specific 
and has little value in early identification of colorectal (or breast cancer) [73]. Another identified 
protein, by Ward et al., was a peak at m/z ratio 5070 Da, which was identified as α1-antitrypsin and is 
involved in the immune response. It has also been implicated in other forms of cancer, so this is 
unlikely to be a specific indicator of CRC. Albrethsen et al. found an increase in serum human 
neutrophil peptides 1, 2 and 3 (HNP 1–3) signals compared to controls via Seldi-TOF mass 
spectrometry. These proteins are involved in regulation of the immune response. HNP 1-3 are found to 
be upregulated in colorectal cells compared to normal epithelial cells [74]. Testing for CRC by 
measuring serum levels with an ELISA assay, yielded a sensitivity of 69% and specificity of 100%, in 
a group of 26 colon cancer patients and 22 controls. However, the control group consisted of healthy 
controls only. Because of this, the high specificity is likely to be overoptimistic. Expression of 
HNP 1-3 has been found in a variety of other tissues, both in inflammatory and neoplastic conditions.  
Engwegen et al. found a non-specific increase of discriminating proteins (N-terminal fragment of 
albumin, apolipoprotein CI, apolipoprotein AI and a yet unidentified protein at 5900 kDa) in other 
cancer types as well. However, some of these acute phase proteins might be used in combination with 
other biomarkers that are more specific biomarkers for CRC. For instance, the m/z ratio 5900 Da peak 
also found by Engwegen et al. (and by Yu et al.) was able to discriminate 76% of CRC from other 
forms of cancer. So far this protein has not been identified (Table 4). 
Table 4. Biomarker identification in colorectal cancer. 
Author  Identified biomarkers (m/z ratio) Int. J. Mol. Sci. 2010, 11                 
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Engwegen et al. World Journal of 
Gastroenterology 2006 [68] 
-  N-terminal albumin fragment (3.1 × 10
3)  
-  Apolipoprotein C-I (3.3 × 10
3/6.6 × 10
3)  
-  Apolipoprotein A-I (28 × 10
3) 
Ward et al. British Journal of 
Cancer 2006 [67] 
-  Alpha1-antitrypsin (50.7 × 10
3) 
-  Apolipoprotein C-I (6.4 × 10
3/6.6 × 10
3) 
-  Transferrin (79.1 × 10
3),  
-  C3 fragment (8.94 × 10
3) 
Albrethsen et al. BMC Cancer 
2005 [75] 
-  HNP 1 (3.37 × 10
3) 
-  HNP 2 (3.44 × 10
3) )
  
-  HNP 3 (3.49 × 10
3) 
6. Discussion 
Numerous studies have described favorable reports on serum protein profiling of breast and 
colorectal cancer patients. These studies used limited amounts of patients and were generally 
case-control studies. The fact that the control groups consisted of healthy people has made it 
impossible to determine whether discriminatory peaks are actually cancer-specific or only “disease-
specific”. It may be that peaks that are now seen as cancer-specific are in fact due to inflammation or 
obstruction caused by cancer. Further studies, not only including healthy persons, but also a control 
group representative of the general patient population, are essential to help to resolve this question. 
Unfortunately most reports lack detailed information regarding the control group used.  
In addition, prospective studies are needed to determine the value of MS in clinical practice. 
However, before these can take place, more research needs to be done on the reproducibility and 
optimal handling and processing methods [76]. In our opinion, an ideal set up to apply MS in a routine 
clinical screening setting would be to first validate the profiles in a population screening. Secondly, 
centralized profiling could be performed in, for example, specialized regional centers. Finally, when 
discriminating proteins are identified, a simple test (e.g., ELISA) could replace profiling for the 
identification of cancer patients. 
Studies on serum samples have identified several potential biomarkers. Most of the markers that 
have been identified so far were (cleaved) proteins that were present in the serum at relatively high 
concentrations, i.e., the so-called high abundant proteins (milli-microgram/mL) [77]. In this respect, 
MS faces the challenge of the high dynamic concentration range since tumor-specific proteins are 
often low abundant (<100 nanogram/mL). In addition, there are indications that the entire spectrum of 
cleaved proteins by tumor-specific exoproteases can be used to identify patients with cancer. This 
implies that not only the identity, but also the size of the biomarker, is important for accurate 
diagnosis [78]. Only testing for the presence of a certain biomarker is likely to be nonspecific, since 
this protein might also present in other diseases and other forms of cancer. However, the spectrum of 
specific fragments of these proteins might be the key to a successful diagnosis instead of conventional 
single biomarkers. Ironically, the breakdown of these proteins occurs after collection of the serum 
sample from the patient. This makes it all the more important to have strict guidelines for handling the 
samples after collection, if results are to be reproducible between different centers. All of these results 
have changed the way of thinking about biomarkers. Finding a single biomarker with MS might be 
impossible, since all tumors have a different molecular background, but it might be possible to Int. J. Mol. Sci. 2010, 11                 
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combine several protein fragments to develop highly reliable tests allowing early cancer diagnosis. 
Although there are doubts about some of these results [79], MS remains a powerful tool in propelling 
these discoveries into the clinical practice. 
7. Conclusion 
In conclusion, several methods exist for the early diagnosis of colorectal and breast cancer. Current 
screening methods have disadvantages such as high-cost, be of an invasive nature, or offer insufficient 
sensitivity or specificity. Because of this, the search for a better diagnostic screening test for both these 
types of cancer is still ongoing. MS has recently been applied for identifying serum biomarkers and 
may lead to a relatively inexpensive (approximately 15 € per sample), minimally-invasive and reliable 
test, for early cancer diagnosis.  
Several case-control studies have reported favorable results for diagnosis of breast and colorectal 
cancer. Comparing the reported sensitivities and specificities of the different research groups with 
current screening techniques, MS would appear to be very promising, however, screening results based 
on these groups, due to the increased a priori chance, are likely to be overoptimistic when compared to 
screening in a normal population. In addition, these studies used different methods, handling protocols, 
and significantly altered peaks for discriminating between cancer patients and healthy controls. In 
order to apply MS in a routine clinical setting, collecting, measuring and processing of data will need 
to be subject to stringent quality control procedures. The current roboting techniques allow high 
throughput. More comparative studies on influential factors and optimal methods are necessary. 
Subsequent prospective studies in representative patient populations can then determine whether MS is 
superior to other screening methods. 
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